Abstract: A method for producing sterile, decellurized bioprosthetic tissue comprising: (a) contacting a human tissue with a hypotonic solution to produce a lysed tissue, (b) contacting the lysed tissue with a first surfactant to produce a surfactant-treated tissue, (c) contacting the surfactant-treated tissue with a nuclease enzyme solution to produce an enzyme-treated tissue, (d) contacting the enzyme-treated tissue with a cleaning solution comprising a second surfactant, a chaotropic agent or a mixture thereof to produce a decellurized tissue and (e) contacting the decellurized tissue with a bioburden reducing agent to produce the final bioprosthetic tissue. Kits to be used in conjunction with said method, as well as, the bioprosthetic tissue produced via said method are also provided.
Abstract: The invention concerns antimicrobial compositions comprising free fatty acids emulsified with membrane lipids or hydrolyzed derivatives thereof, and pharmaceutical formulations comprising same. The compositions can be used in the treatment of prophylaxis of microbial infections. They can also regulate the rate of blood clotting rendering them suitable for incorporation in catheter locking solutions and for use in wound care.
Abstract: A method for producing dry earthworm powder, by which dry earthworm powder having high-titer enzymes can be produced while removing toxic substances contained in the bodies of earthworms, is provided. The method comprises: contacting a live earthworm with a chloride(s) of at least one metal selected from the group consisting of potassium, sodium, magnesium and calcium; and subsequently contacting the live earthworm with powder of a hydroxycarboxylic acid(s) and diluting the resulting mixture with water to adjust pH to 2 to 5, followed by leaving the live earthworm to stand for 3 to 180 minutes, washing the live earthworm with water, grinding the washed live earthworm and freeze-drying the obtained ground product.
Abstract: The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels.
Type:
Grant
Filed:
December 15, 2015
Date of Patent:
October 25, 2016
Assignee:
ACell, Inc.
Inventors:
Kimberly A. Kentner, Katherine A. Stuart, Abram D. Janis
Abstract: The invention is directed to a method to establish a biologically significant association of gene expression levels among two or more genes, the method comprising assaying a sample for expression levels of two or more genes and identifying statistically-significant associations using a correlation coefficient in the range of about 0.6 to about 1.0, wherein a correlation coefficient in that range signifies a biologically significant correlation.
Abstract: Provided herein are compositions comprising substantially non-viable Gram-negative bacterial organisms that have a substantial reduction in endotoxin activity and/or pyrogenicity and methods for treating a cancer using the same. Also provided are methods for treating cancer provided herein, comprising administering to a mammal diagnosed with cancer, substantially non-viable Gram-negative bacteria having a substantial reduction in endotoxin activity and/or pyrogenicity, in an amount sufficient to inhibit growth or metastasis of the cancer. An additional method is provided comprising administering viable or non-viable Gram-negative bacterial organisms that have a genetic defect that results in a substantial loss of lipopolysaccharide within the outer membrane of the bacteria. Further provided are methods for reducing endotoxin activity and/or pyrogenicity in Gram-negative bacteria comprising treatment with polymyxin and glutaraldehyde.
Abstract: The subject of the present invention is a bioactive cell homogenate produced from cells belonging to the MIC-1 stem cell line derived from growing deer antlers (Cervidae) deposited at the DSMZ under the accession DSM ACC2854, a method of producing and using it. The present invention also encompasses a pharmaceutical or cosmetic composition containing the above-mentioned homogenate.
Type:
Grant
Filed:
October 29, 2014
Date of Patent:
February 16, 2016
Assignee:
STEM CELLS SPIN S.A.
Inventors:
Wojciech Dziewiszek, Marek Cegielski, Marek Bochnia
Abstract: Compositions containing acellularized biomaterial derived from differentiating pluripotent cells, for example, embryonic stem cells are provided. The acellularized biomaterial can be used to promote wound healing, promote tissue regeneration, or inhibit scarring. Methods for using the acellularized biomaterial for treating degenerative diseases are also provided.
Type:
Grant
Filed:
November 8, 2006
Date of Patent:
December 15, 2015
Assignee:
Georgia Tech Research Corporation
Inventors:
Todd Christopher McDevitt, Rehka Ramachandran Nair
Abstract: The present inventive concept provides a multiple separation device and a method of separating a blood cancer cell using the same. In the device and the method, a blood sample is put in a fine channel and then cancer cells can be separated according to the type of cancer by controlling a flow velocity of the blood or a magnetic force of ferromagnetic pattern.
Type:
Grant
Filed:
March 6, 2013
Date of Patent:
October 13, 2015
Assignee:
ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE
Inventors:
Seong-Mok Cho, Dae-Sik Lee, Jeong Won Park, Moon Youn Jung
Abstract: The present invention relates to a composition comprising an extract of a mixture of Undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis, wherein the composition has the excellent effect of treating atopic dermatitis through the synergistic interaction of the anti-inflammatory effect of Undaria pinnatifida sporophylls and the cell regenerative effect of ascidian shells. The composition of the invention is not involved in the suppression of cytokine production. However, it is assumed that the composition has the effects of suppressing inflammation as well as regenerating skin.
Type:
Application
Filed:
October 31, 2012
Publication date:
May 21, 2015
Inventors:
Beyong Dae Choi, Seong Hun Jeong, Shi Hyang Park, Myung Sook Kim, Soon Ok Choi
Abstract: This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO2 or CO2 plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill oils by using supercritical CO2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.
Type:
Grant
Filed:
March 28, 2008
Date of Patent:
May 19, 2015
Assignee:
AKER BIOMARINE ANTARTIC AS
Inventors:
Inge Bruheim, Mikko Griinari, Snorre Tilseth, Sebastiano Banni, Jeffrey Stuart Cohn, Daniele Mancinelli
Abstract: The invention is in the field of therapeutic treatment of tumors. It has been found that the conditioned medium resulting from culturing an adult stem cell capable of differentiating into a plurality of differentiated cell types in a liquid cell culture medium and/or the adult stem cell from which the conditioned medium is obtainable, exert a remarkable anti-tumor effect. The adult stem cell derived conditioned medium preferred in this therapeutic application is a cell free conditioned medium derived from a human liver stem cell (HLSC).
Type:
Grant
Filed:
December 7, 2010
Date of Patent:
May 19, 2015
Assignee:
FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
Inventors:
Maria Beatriz Herrera Sanchez, Valentina Fonsato, Ciro Tetta, Giovanni Camussi
Abstract: The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
May 19, 2015
Assignee:
Health Diagnostic Laboratory, Inc.
Inventors:
Michael S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
Abstract: A method for treating intact irritated or inflamed skin with a composition comprising at least one Histamine Receptor pathway inhibitor; at least one Lipoxygenase pathway inhibitor; at least one Cyclooxygenase pathway inhibitor and at least one Chemotaxis pathway inhibitor.
Type:
Application
Filed:
November 14, 2013
Publication date:
May 14, 2015
Applicant:
ELC Management, LLC
Inventors:
Donald F. Collins, Daniel M. Maes, Neelam Muizzuddin
Abstract: This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO2 or CO2 plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill oils by using supercritical CO2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.
Abstract: Novel implantable tissue fixation methods and compositions are disclosed. Methods and compositions of tissue, fixed using polymeric and/or variable length crosslinks, and di- or polymercapto compounds are described. Also described are the methods and compositions wherein the tissue is fixed using biodegradable crosslinkers. Methods and compositions for making radio-opaque tissue are also described. Methods and compositions to obtain a degradable implantable tissue-synthetic biodegradable polymer composite are also described. Compositions and methods of incorporating substantially water-insoluble bioactive compounds in the implantable tissue are also disclosed. The use of membrane-like implantable tissue to make an implantable drug delivery patch are also disclosed. Also described are the compositions and methods to obtain a coated implantable tissue. Medical applications implantable tissue such as heart valve bioprosthesis, vascular grafts, meniscus implant, drug delivery patch are also disclosed.
Type:
Grant
Filed:
February 8, 2013
Date of Patent:
May 5, 2015
Assignee:
Pathak Holdings LLC
Inventors:
Chandrashekhar P. Pathak, Sanjay M. Thigle
Abstract: Provided is a matrix for promoting survival and differentiation of cells transplanted thereon, comprising a base matrix and a cell-made matrix thereon. Methods and means for making and using same are also provided. Also provided are conditioned media, related compositions, related methods, and related packaging products.
Type:
Application
Filed:
December 24, 2014
Publication date:
April 30, 2015
Inventors:
Ilene SUGINO, Vamsi GULLAPALLI, Marco ZARBIN
Abstract: This invention relates to use of pharmaceutical compositions in preparing pharmaceuticals for treating diabetic ulcer in limb or on body surface, or in preparing medical dressing. The pharmaceutical compositions consist of (A) 3 to 15% by weight of edible beeswax and (B) 85 to 97% by weight of sesame oil extract of Huangqin, Huanglian, Huangbai, earthworm and poppy capsule, based on the total weight of the pharmaceutical compositions. In the sesame oil extract, each of Huangqin, Huanglian, Huangbai, earthworm and poppy capsule is in an amount of 2 to 10% by weight of dry raw material based on the total weight of sesame oil. This invention also relates to a medical dressing for treating diabetic ulcer and corresponding medicine box enclosing the said dressing.
Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart-type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin-12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.
Type:
Grant
Filed:
November 10, 2009
Date of Patent:
March 31, 2015
Assignee:
Astute Medical, Inc.
Inventors:
Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura
Abstract: The invention is directed to immortalized cell compositions and compositions derived therefrom. The invention is further directed to methods of making and using such immortalized cell compositions and compositions derived therefrom. Such immortalized cell compositions include but are not limited to Immortalized Amnion-derived Multipotent Progenitor cells (herein referred to as I-AMP cells) and conditioned media derived therefrom (herein referred to as I-Amnion-derived Cellular Cytokine Solution or I-ACCS).
Abstract: [Task] A method for producing dry earthworm powder, in which there is no risk of reduction of the enzymatic activity of earthworms and the enzymatic activity of the dry earthworm powder obtained therefrom is increased, is provided. [Means for Resolution] Disclosed is a method for producing dry earthworm powder, in which earthworms which have been subjected to a treatment for removing casting soil are used as a raw material to produce dry earthworm powder, the living organisms of the earthworms or crushed products thereof which have been subjected to a treatment for removing casting soil are subjected to a pressurization treatment under a pressure condition of 10 MPa to 500 MPa and a temperature condition of 0° C. to 70° C., and the earthworms or crushed products thereof after the pressurization treatment are used as a raw material of the dry earthworm powder.
Type:
Application
Filed:
August 22, 2014
Publication date:
March 5, 2015
Applicants:
WAKI PHARMACEUTICAL CO., LTD., NATIONAL INSTITUTE OF TECHNOLOGY
Abstract: A molecular construct comprises a donor label, an acceptor label, a linker peptide disposed between the donor and the acceptor, the linker having a cleavage site sequence, and a spacer between at least one of (a) the donor and the cleavage site sequence and (b) the acceptor and the cleavage site sequence. Preferably, the construct is selected from the group consisting of CFP-(SGLRSRA)-SNAP-25-(SNS)-YFP, and CFP-(SGLRSRA)-synaptobrevin-(SNS)-YFP. In preferred embodiments, the linker peptide is a substrate of a botulinum neurotoxin selected from the group consisting of synaptobrevin (VAMP), syntaxin and SNAP-25, or a fragment thereof that can be recognized and cleaved by the botulinum neurotoxin. Advantageously, the spacer increases the electronic coupling between the donor label and the acceptor label relative to a corresponding construct without the spacer.
Abstract: The present invention provides methods for differentiating a pediatric subject with pediatric septic shock from a healthy pediatric subject or one having sudden inflammatory response syndrome (SIRS). Also provided is a method of predicting pediatric septic shock mortality in a pediatric septic shock patient.
Type:
Grant
Filed:
January 22, 2014
Date of Patent:
March 3, 2015
Assignees:
UTI Limited Partnership, Children's Hospital Medical Center
Inventors:
Beata Mickiewicz, Hans J. Vogel, Hector R. Wong, Brent W. Winston
Abstract: The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.
Type:
Application
Filed:
December 21, 2012
Publication date:
January 29, 2015
Inventors:
Rafael Yuste, Roberto Etchenique, Luis Baraldo
Abstract: We describe the use of an exosome for the preparation of a pharmaceutical composition to promote or enhance would healing or hair growth, or both, in an individual. The exosome may be derived from a stem cell such as a mesenchymal stem cell (MSC).
Type:
Application
Filed:
July 28, 2014
Publication date:
January 22, 2015
Inventors:
Sai Kiang LIM, Mathew Sze Wei YEO, Tian Sheng CHEN, Ruenn Chai LAI
Abstract: Gastric resistant film-forming compositions are described herein. The composition comprises a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent. Suitable gastric resistant natural polymers include polysaccharides such as pectin and pectin-like polymers. The film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (Softlet®) comprising an active agent and one or more pharmaceutically acceptable excipients. Alternatively, the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition. The compositions are not only gastric resistant but may also prevent gastric reflux associated with odor causing liquids, such as fish oil or garlic oil, encapsulated in a unit dosage form and esophageal irritation due to the reflux of irritant drugs delivered orally.
Abstract: The embodiments disclose a supplement and medication cultivated plant delivery system including using a cultivation system for cultivating integrated enriched food products including fruits, produce and aquatic species and animal feeds, controlling and testing the cultivation system environment including an aqua cultivation media, incorporating a controlled feed system to raise aquatic species and animals using integrated enriched food products feeds, harvesting cultivated integrated enriched food products and cultivated integrated enriched food products feed raised aquatic species and animals, delivering the cultivated integrated enriched food stuffs to markets for providing alternative cultivated integrated enriched food stuffs to prevent and treat health conditions on a long-term sustainable basis, and empowering people to improve their health conditions while simply eating cultivated integrated enriched food stuffs in their daily regimen of eating.
Type:
Application
Filed:
July 14, 2014
Publication date:
January 15, 2015
Inventors:
Wayne Garland, Allen Mark Jones, G. Douglas Hayden
Abstract: This invention is directed to coral scaffolds seeded with precursor cells in culture in the presence of a chelator and uses thereof in inducing or enhancing bone and/or cartilage formation in a subject, and kits related thereto. This invention is also directed to use of cadherin-upregulating coral for treating cancer or inhibiting cancer progression. This invention is also directed to use of aragonite or calcite-producing species for in vivo calcium release, and its application to the treatment of skin diseases, disorders or conditions.
Type:
Grant
Filed:
November 18, 2008
Date of Patent:
January 13, 2015
Assignee:
Ben Gurion University of the Negev Research and Development Authority
Abstract: The present invention relates to active compound combinations for reducing the damage of plants and plant parts as well as losses in harvested fruits or vegetables caused by insects, nematodes or phytopathogens and which have fungicidal or nematicidal or insecticidal activity including any combination of the three activities, in particular within a composition, which comprises (A) Fluopyram and (B) one biological control agent, in particular bacteria, fungi or yeasts, protozoa, viruses, entomopathogenic nematodes, inoculants, botanicals and products produced by microorganisms including proteins or secondary metabolites. Moreover, the invention relates to a method for curatively or preventively controlling insects, nematodes or phytopathogens on the plant, plant parts, harvested fruits or vegetables, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed.
Abstract: This disclosure features human milk permeates and compositions containing the same obtained from fractionated whole human milk. The oligosaccharide rich permeate and permeate compositions of the present invention are useful as nutritional supplements for pre-term and full term infants, for establishing or maintaining gut flora and for treating the symptoms of inflammatory bowel disease.
Type:
Grant
Filed:
December 2, 2009
Date of Patent:
January 6, 2015
Assignee:
Prolacta Bioscience
Inventors:
Joseph Fournell, Scott Eaker, Scott Elster, David J. Rechtman
Abstract: Menstrual fluid simulants may consistently emulate the physical characteristics of real menstrual fluid, including but not limited to, viscosity, stringiness, surface tension and size and concentration of particulate matter. In addition, the constituents comprising the menstrual fluid simulants may be changed in order to mimic the variations in real menstrual fluid observed from woman to woman and from an individual woman over time. The menstrual fluid simulants are of use in the testing of personal care absorbent products.
Type:
Grant
Filed:
January 4, 2010
Date of Patent:
December 30, 2014
Assignee:
The Procter & Gamble Company
Inventors:
William Hollis Hood, Marsha Jean Spears, William Joseph Worley
Abstract: The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. In preferred embodiments, the methods and agents comprise active extracts produced from fish eggs. The invention further provides processes for making active fish egg extracts.
Abstract: A corneal cover or corneal implant to be placed within or onto the surface of the cornea is made of bony fish scales and a contact lens is made of bony fish scales.
Type:
Grant
Filed:
March 3, 2010
Date of Patent:
December 23, 2014
Assignee:
Body Organ Biomedical Corp.
Inventors:
Chien-Cheng Lin, Horng-Ji Lai, Shang-Ming Lin, Feng-Huei Lin
Abstract: Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.
Type:
Grant
Filed:
March 11, 2013
Date of Patent:
December 16, 2014
Assignees:
Carnegie Mellon University, Allegheny-Singer Research Institute, Carmell Therapeutics Corporation
Inventors:
Phil G. Campbell, James E. Burgess, Lee E. Weiss, Jason Smith
Abstract: An apparatus may allow separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample and mesenchymal stem cells from bone reaming material. A buoy system that may include a first buoy portion and a second buoy member operably interconnected may be used to form at least three fractions from a sample during a substantially single centrifugation process. Therefore, the separation of various fractions may be substantially quick and efficient.
Type:
Application
Filed:
August 18, 2014
Publication date:
December 4, 2014
Inventors:
Michael D. LEACH, Joel C. HIGGINS, Matthew SWIFT, Nathan GORDON
Abstract: The subject of the present invention is a bioactive cell homogenate produced from cells belonging to the MIC-1 stem cell line derived from growing deer antlers (Cervidae) deposited at the DSMZ under the accession DSM ACC2854, a method of producing and using it. The present invention also encompasses a pharmaceutical or cosmetic composition containing the above-mentioned homogenate.
Type:
Grant
Filed:
January 26, 2011
Date of Patent:
December 2, 2014
Assignee:
Stem Cells Spin S. A.
Inventors:
Wojciech Dziewiszek, Marek Cegielski, Marek Bochnia
Abstract: Skin care creams and atomizable liquids, based on mineral based ingredients such as those in gemstones and gold, and organically based ingredients such as organic solvents, eggs, and others. The personal care substances are in fluid form, including a carrier fluid together with active ingredients. The final fluids may be topically applied, or may be used as additives to other personal care substances.
Abstract: The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels.
Type:
Application
Filed:
July 16, 2014
Publication date:
November 20, 2014
Inventors:
Kimberly A. Kentner, Katherine A. Stuart, Abram D. Janis
Abstract: Subject of the present invention is a biomarker for graft failure and/or mortality after organ transplantation. Procalcitonin was found to be a useful marker for the prediction or risk stratification for graft failure and/or mortality of a subject who has received an organ transplant and monitoring and therapy guidance of such subject.
Type:
Grant
Filed:
May 29, 2009
Date of Patent:
November 18, 2014
Assignee:
B.R.A.H.M.S. GmbH
Inventors:
Joachim Struck, Stephanus Johannes Bakker
Abstract: Biodegradable pharmaceutical compositions comprising 1,3-propanediol and its esters are provided. The 1,3-propanediol and its esters in the pharmaceutical composition are biologically derived, and as such, the pharmaceutical compositions exhibit a low anthropogenic CO2 emission profile.
Type:
Application
Filed:
July 14, 2014
Publication date:
November 6, 2014
Applicant:
DuPont Tate & Lyle Bio Products Company, LLC
Inventors:
Robert Miller, Joseph Desalvo, Gyorgyi Fenyvesi, Melissa Joerger, Raja Hari Poladi, Ann Wehner
Abstract: The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. The agents include compositions of cells, eggs, cell extracts, egg extracts, and extract components such as purified nucleic acids, polypeptides, lipids, carbohydrates or other natural products.
Abstract: The present invention refers to a peptide of general formula (I) R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-Yp-Zq-R2, cosmetic compositions which comprises said peptide, method of preparation of said peptides and its use in the treatment and/or prevention of itching, inflammation, pain, diseases and/or disorders of the respiratory airways.
Type:
Application
Filed:
October 31, 2012
Publication date:
October 30, 2014
Inventors:
Antonio Vicente Ferrer Montiel, José María García Antón, Raquel Delgado González
Abstract: Tissue repair in-vivo depends on acute inflammation, but in many clinical situations the other major components of healing such as blood supply, anabolic hormones, growth factors, and stem cells are lacking. This invention includes compositions consisting of an agent which induces an inflammatory healing response combined with an autologous platelet lysate at a specific concentration which may have demonstrated in-vitro abilities to expand autologous tissue repair cells.
Abstract: Diets high in saturated fat and fructose have been implicated in the development of obesity and nonalcoholic steatohepatitis (NASH) in humans. Provided herein are biomarkers, methods, and animal models useful for the investigation and non-invasive detection of NASH, including a non-invasive biomarker that could be used to establish disease severity, follow progression, and evaluate response to treatment in clinical trials for this increasingly prevalent disease.
Type:
Grant
Filed:
January 26, 2011
Date of Patent:
October 28, 2014
Assignee:
Children's Hospital Medical Center
Inventors:
Rohit Kohli, Stavra A. Xanthakos, Michael V. Miles
Abstract: Disclosed are perivascular medicinal cells (PVMCs), methods of isolating PVMCs, and a composition comprising PVMCs having medicinal capabilities. Specifically, the disclosure provides a method of isolating PVMCs from an umbilical cord blood vessel or from bone. The disclosure further provides a method of making an enhanced, autologous bone graft, a method of stimulating bone regeneration comprising administering a therapeutically effective amount of bone-derived PVMCs, a method of reconstructing bone tissue, and methods of treating a disease that affects cellular function. PVMCs capable of secreting a site-dependent trophic factor are also described.
Abstract: An immunoanalytical system in which, after a sample such as a patient's serum is subjected to a pretreatment by an immunological pretreatment device, the sample is subjected to light detection by an immunological photometric detection system. Subsequently, the mass spectrometric pretreatment device performs a pretreatment, and the mass spectrometric detection system performs mass spectrometry. The mass spectrometric detection system performs mass spectrometry on components contained in a supernatant. A signal intensity and peak area for each of components are calculated from an obtained chromatograph. A quantitative value measured based on the immunoanalytical method is calculated for each of the components on the basis of the relative ratios of the components.
Abstract: Provided is a method for noninvasive prediction or diagnosis of inflammation and/or infection in amniotic fluid leaked through the cervix into the vagina to predict the concentration of inflammatory markers in the amniotic fluid inside uterus by measuring the concentration of inflammatory markers (various cytokines). Further provided is a method for prediction or diagnosis of inflammation and/or infection in amniotic fluid by measuring the concentration of markers (IL-6, IL-1? IL-8, MCP-1, GRO-?) in the amniotic fluid leaked through the cervix into the vagina in patients with premature rupture of membranes. The method can be performed more stably on pregnant women, as compared to the conventional method for prediction or diagnosis of inflammation and/or infection using invasively collected amniotic fluid.
Type:
Grant
Filed:
September 5, 2012
Date of Patent:
October 14, 2014
Assignees:
Snu R&DB Foundation, Ob Med
Inventors:
Bo Hyun Yoon, Joong Shin Park, Jong Kwan Jun, Chan Wook Park
Abstract: The present invention is directed towards methods for measuring and assaying PAS Kinase activity. The methods are useful, for example, for detecting PASK activity in a cell, and for screening for small molecule regulators of PAS kinase activity, as well as characterizing endogenous factors and stimuli that modulate PAS kinase activity, and identifying and optimizing the activity of potential PAS kinase inhibitors.
Abstract: The present invention relates to a fluorescent cell binding assay combining pre-labeling and Western blotting. Intact cells are incubated with pre-labelled binders preferably followed by SDS PAGE (sodium dodecylsulphate polyacrylamide gel) separation and Western blotting. More closely, the invention relates to a cell binding assay in which the degree or amount of binding of one or more cell interacting protein or protein component to the cell surface is measured with the ability to correlate the degree of cell binding to the sample load/total number of cells.